Journal article
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) - Quality of life during the first 4 months after fracture
F Borgström, I Lekander, M Ivergård, O Ström, A Svedbom, V Alekna, ML Bianchi, P Clark, MD Curiel, HP Dimai, M Jürisson, R Kallikorm, O Lesnyak, E McCloskey, E Nassonov, KM Sanders, S Silverman, M Tamulaitiene, T Thomas, ANA Tosteson Show all
Osteoporosis International | Published : 2013
Abstract
The quality of life during the first 4 months after fracture was estimated in 2,808 fractured patients from 11 countries. Analysis showed that there were significant differences in the quality of life (QoL) loss between countries. Other factors such as QoL prior fracture and hospitalisation also had a significant impact on the QoL loss. Introduction: The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) was initiated in 2007 with the objective of estimating costs and quality of life related to fractures in several countries worldwide. The ICUROS is ongoing and enrols patients in 11 countries (Australia, Austria, Estonia, France, Italy, Lithuania, Mexico, Russ..
View full abstractRelated Projects (3)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
We are grateful to the Quality of Life and Epidemiology Working Group<SUP>1</SUP> of the Committee of Scientific Advisors for the International Osteoporosis Foundation under whose supervision this study was undertaken. The ICUROS is sponsored by Amgen, Eli Lilly, Medtronic (formerly Kyphon), Novartis, Sanofi-Aventis, Servier and Wyeth. In Australia, the study is supported by project grant no. 628422 from the National Health and Medical Research Council. In Austria, the study is sponsored by Central Association of Austrian Social Security Institution (Hauptverband der osterreichischen Sozialversicherungstrager), Austrian Society for Bone and Mineral Research (AuSBMR), Merck Sharp & Dohme, Servier GmbH, Medtronic (formerly Kyphon) GmbH, Amgen GmbH, Novartis GmbH, Nycomed GmbH, Roche GmbH, Sanofi-Aventis GmbH and Daiichi-Sankyo GmbH. In Mexico, the study was supported by CONACyT grant number El 2008-01-87106, and we are grateful to Gabriela Chico Master Student Mexico City, Fernando Carlos MHE Mexico City. In Lithuania, the work was supported by National Osteoporosis Center and gratitude is extended to Maryte Garliene for skilful technical assistance. In the Russia, the following team members provided valuable contributions to the study: Dr. Natalia Toroptsova, Dr. Oxana Nikitinskaya, Dr. Olga Dobrovolskaya (Institute of Rheumatology, RAMS, Moscow), Prof. Larissa Menshikova, Dr. Julia Varavko (Medical Institute of Postgraduate Training, Irkutsk), Prof. Olga Ershova, Dr. Ksenia Belova (Yaroslavl State Medical Academy, Yaroslavl), Dr. Alexander Solodovnikov, Dr. Ksenia Usenko (Ural State Medical Academy, Yekaterinburg), Prof. Georgij Golubev, Dr. Vyacheslav Grebenshikov (Rostov-on-Don State Medical University, Rostov-on-Don), Prof. Eugenij Zotkin, Dr. Irina Zubkova (North-West Federal Medical University, Saint-Petersburg), Prof. Alexander Kochish, Dr. Sergej Ivanov (Vreden Institute of Traumatology and Orthopedics, Saint-Petersburg) and Dr. Radik Nurligayanov (City Clinical Hospital # 21, Ufa). In the USA, Amgen Inc., Ingenix Pharmaceutical Services, Eli Lilly and Company, Medtronic Spine LLC and Wyeth Pharmaceuticals Inc. sponsored the study. Hoffmann La Roche and Amgen provided support. In Estonia the study was supported by Estonian Science Foundation grant # 9368.